

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/102233/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Little, Dene R., Bullen, Hayley E., Harvey, Katherine L., Beddoe, Travis, Crabb, Brendan S., Rossjohn, Jamie ORCID: <https://orcid.org/0000-0002-2020-7522> and Gilson, Paul R. 2016. Disrupting the allosteric interaction between the plasmodium falciparum cAMP-dependent kinase and its regulatory subunit. *Journal of Biological Chemistry* 291 (49) , p. 25375. 10.1074/jbc.M116.750174 file

Publishers page: <http://dx.doi.org/10.1074/jbc.M116.750174>
<<http://dx.doi.org/10.1074/jbc.M116.750174>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Disrupting the allosteric interaction between the *Plasmodium falciparum* cAMP-dependent kinase and its regulatory subunit.

Dene R. Littler^{1*}, Hayley E. Bullen^{2*}, Katherine L. Harvey^{2,3}, Travis Beddoe⁴, Brendan S. Crabb^{1,2,3}, Jamie Rossjohn^{1,5,6} and Paul R. Gilson^{1,2†}.

1. Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia,

2. Burnet Institute, Melbourne, Victoria 3004, Australia

3. University of Melbourne, Melbourne, Victoria 3010, Australia

4. Centre for AgriBioscience, La Trobe University, Bundoora, Victoria 3086, Australia.

5. Institute of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, Wales,

6. ARC Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria 3800, Australia

* Contributed equally to this work.

† Address correspondence to: paul.gilson@burnet.edu.au

Running title: *P. falciparum* cAMP-dependent kinase

Keywords: protein kinase A (PKA), malaria, cyclic AMP (cAMP), plasmodium, protein structure

Abstract

The ubiquitous second messenger cAMP mediates signal transduction processes in the malarial parasite that regulate host erythrocyte invasion and the proliferation of merozoites. In *Plasmodium falciparum* the central receptor for cAMP is the single regulatory subunit (R) of Protein kinase A (PKA). To aid the development of compounds that can selectively dysregulate parasite PKA signalling we solved the structure of the PKA regulatory subunit in complex with cAMP and a related analog that displays antimalarial activity: Sp-2Cl-cAMPS. Prior to signalling, PKA-R holds the kinase's catalytic subunit (C) in an inactive state by exerting an allosteric inhibitory affect. When two cAMP molecules bind to PKA-R they stabilise a structural conformation that facilitates its dissociation, freeing PKA-C to phosphorylate down-stream substrates such as Apical Membrane Antigen 1. While PKA activity was known to be necessary for erythrocytic proliferation we show that uncontrolled induction of PKA activity using membrane permeable agonists is equally disruptive to growth.

Introduction

Despite significant inroads in mitigating their toll on human health, *Plasmodium* parasites, the causative agents of malaria, remain deadly human pathogens (1) (2). Their complex parasitic life cycle alternates between mosquito and vertebrate hosts, however it is the asexual intraerythrocytic stage with which disease is associated. To ensure timely and successful transmission and propagation, the parasite must constantly monitor its surroundings in order to coordinate its development. At the molecular level signal transduction pathways orthologous to those found in other eukaryotes are responsible for dynamic post-transcriptional phosphorylation reactions that control key developmental proteins (3). The phylum Apicomplexa to which *Plasmodium* belongs, is evolutionary distant to most commonly studied organisms (4) and significant phylogenetic diversity thus separates the *Plasmodium* kinome from other studied systems. This diversity can be exploited though if inhibitory compounds can be developed that selectively block parasite regulatory

enzymes while leaving orthologous human variants unaffected (5).

As in other eukaryotic species *Plasmodium* developmental pathways utilise the diffusible second messenger 3'-5'-cyclic adenosine monophosphate (cAMP), the main effector for which is the cAMP-dependent kinase: protein kinase A (6). cAMP-dependent signalling is generally activated when ligands bind to membrane bound receptors that go on to activate intracellular adenylate cyclases, yielding a localised rise in the cAMP concentration and hence activation of PKA. *P. falciparum* PKA activity is instrumental to a number of molecular mechanisms, including merozoite egress, motility and red blood cell invasion (7,8), schizogony (7) and the progression from schizonts to invasive merozoites (9). Specifically, during merozoite invasion *Pf*PKA has been implicated in regulating microneme secretion of erythrocyte host-recognition receptors (10), and once inside the host cell PKA signalling pathways influence parasite growth and differentiation (11) possibly by initiating the formation of new permeation pathways (12). Following differentiation into gametocytes cAMP-dependent kinase activity has also been found to regulate the host cell membranes stiffness in order to prevent splenic clearance (13).

PKA orthologues are ubiquitous amongst eukaryotes and are composed of a catalytic kinase subunit (PKA-C) in association with a regulatory subunit (PKA-R) containing two cAMP-binding sites. Compounds that specifically inhibit the *Plasmodium* PKA-C kinase domain are known to block parasite development (14). Less is known about the action of the *Pf*PKA-R subunit and whether this can also be therapeutically targeted. Mammalian

PKA has been extensively studied and serves as a useful frame of reference from which to understand the distinct *P. falciparum* PKA system (15). In mammals, the regulatory PKA-R subunit is a highly dynamic molecular switch (16) (17) that serves as a competitive inhibitor of the catalytic subunit, holding it inactive in the absence of cAMP but rapidly releasing its inhibitory check as the cAMP concentration rises. Mammals have four R-subunit isoforms within their PKA systems, which are split into related type I and type II pairs (RI α and I β , II α and II β respectively) (18). Each of these isoforms are functionally distinct and influence their respective holoenzymes cellular localization, sensitivity to activation and regulatory feedback mechanisms (19). In contrast, the unicellular *Plasmodium* parasites contain a single *Pf*PKA-R subunit whose features appear to be a hybrid of the mammalian subtypes (15). Primary structure analysis indicates that *Plasmodium* PKA-R has a its own loosely structured N-terminal sequence but, as in mammalian R subunits, the C-terminus contains two consecutive cyclic nucleotide-binding domains (CBDs). These CBDs share ~35% sequence identity with their mammalian equivalents, and ~54% identity with non-*Plasmodium* Apicomplexans.

The CBDs themselves are an ancient signalling module often found in enzymes regulated by cAMP or cGMP (20), their fold consists of a conserved 8-stranded β -barrel along with three or more accessory α -helices. Cyclic nucleotides typically insert phosphate-first into the barrel's core and in doing so induce structural rearrangements of the α -helices to induce the second messenger response. In human PKA holoenzymes, the catalytic kinase subunit (C) is held inactive

through its association with the *apo* dumbbell shaped PKA-R subunits, a shape derived from the two CBDs lying on either side of a rigid connecting helix (21). This dumbbell shape exposes two inhibitory regions: a pseudosubstrate sequence N-terminal to CBD1 that locks into the kinase domain's active site; and the helix between the two CBDs that binds to the large lobe of the kinase domain and prevents catalytically necessary 'breathing' motions. These mutual inhibitory effects are lost when cyclic nucleotide binding causes the regulatory domain's dumbbell shape to collapse into a more compact form that masks the kinase domain-interacting regions facilitating subunit dissociation (17). The catalytic domain is thus freed from its allosteric restraint allowing it to transmit and amplify the cAMP signal to multiple downstream targets via its kinase activity. We sought to assess to what extent this molecular activation mechanism is conserved in *PfPKA-R*. Furthermore we examine the effects on parasite growth of membrane permeable compounds that cause PKA dysregulation through premature activation of the holoenzyme.

Results

Expression of the Plasmodium falciparum PKA regulatory subunit.

The *P. falciparum* 3D7 genome contains a single 441 amino acid *PfPKA-R* subunit (PlasmoDB# PF3D7_1223100) known to associate with a cAMP-inducible kinase activity (12). The *PfPKA-R* sequence encompasses two predicted cyclic-nucleotide binding domains: CBD1 (residues 166-294) and CBD2 (residues 310-441) (Fig. 1). We cloned, expressed and purified four *PfPKA-R* constructs spanning either one or both CBD (residues 2-441, 69-441, 141-441 and 297-441).

The constructs *PfPKA-R.141.441* and *PfPKA-R.297.441* expressed with 5-10 mg/L yields and were thus favoured for further study (Fig. 1).

Following purification of the *PfPKA-R* constructs UV-visible light absorbance spectra indicated the presence of a 260nm absorbance peak presumed to be bound nucleotide scavenged from the *E. coli* lysate. To liberate these *PfPKA-R*-bound nucleotides, we performed a standard soluble expression protocol but retained *PfPKA-R.141.441* on the immobilised metal affinity column, washed with progressively higher concentrations of urea-containing buffers, and slowly returned to a standard buffer prior to protein elution and further purification. Absorbance measurements indicated that ~50 column volumes of 8M urea were required to liberate all bound nucleotide. This refolded apo-*PfPKA-R.141.441* sample represents a conformation of *PfPKA-R* with two empty CBD binding sites primed for re-association with the PKA-C (22). This on column refolding reduced total protein yield (~1mg/L) from that of a standard soluble purification (~5mg/L). We append the prefix "**apo-**" to distinguish between *PfPKA-R* purifications that required nucleotide dissociation (kinase and affinity assays and drug-bound structures).

Recombinant PfPKA-R is functionally active.

To verify that the recombinant apo-*PfPKA-R.141.441* was active, we aimed to investigate if it could block PKA-C activity and thus inhibit *PfPKA*-driven phosphorylation. Unfortunately, we were unable to bacterially express soluble recombinant *PfPKA-C* and instead utilised late-stage *P. falciparum* schizont lysates as

our kinase source. The cytoplasmic tail of Apical Membrane Antigen 1 (AMA1), which is a highly validated target of *Pf*PKA (23) (8) (24) was used as our kinase substrate. The AMA1-tail is phosphorylated by *Pf*PKA at amino acid S610 and this event is required for merozoite invasion of erythrocytes by *P. falciparum* (8). For our assays, the 56 amino-acid (aa) AMA1-tail was expressed as a fusion with glutathione S transferase (GST) and immobilised in the wells of an ELISA microplate (Fig. 2A). Schizont lysate was added to each well with varying concentrations of cAMP to stimulate *Pf*PKA phosphorylation, and/or recombinant *Pf*PKA-R to inhibit phosphorylation. Following the reaction, phosphorylation of S610 was detected with a highly specific antibody raised to a synthetic S610p phosphopeptide (Fig. 2A) (23). In the absence of supplementary apo-*Pf*PKA-R or cAMP, phosphorylation of AMA1 was quite low, indicating minimal levels of *Pf*PKA-C activity in the parasite lysates (Fig. 2B). This activity was however strongly boosted by addition of supplementary cAMP. Furthermore, addition of our apo-*Pf*PKA-R fragment strongly suppressed AMA1 phosphorylation in a concentration-dependent manner presumably because it allosterically inhibited native *Pf*PKA-C (Fig. 2B). Importantly, this inhibitory activity could be reversed in a concentration-dependent fashion by increasing amounts of supplementary cAMP (Fig. 2B).

To ensure that this inhibitory effect was specifically due to the action of the recombinant protein and not a non-specific contaminant, we heated the recombinant protein and repeated the assay. The heat-denatured protein was poorly efficient at inhibiting AMA1

phosphorylation when compared with the untreated protein validating that inhibition was due to recombinant apo-*Pf*PKA-R (Fig. 2B). Our recombinantly produced regulatory subunit thus associates with the parasite's catalytic subunit influencing its activity.

Structure of the PfPKA-R subunit.

Broad screens identified conditions facilitating protein crystal growth for the *Pf*PKA-R.141.441 and 297.441 constructs in complex with cAMP, with X-ray diffraction data then obtained to 2.0 Å and 1.1 Å resolution, respectively. Initial electron density maps were calculated using phases obtained via molecular replacement (see materials and methods for details).

Our final model of *Pf*PKA-R.141.441 has clear electron density for all structural elements of the two CBD modules (Fig. 3A,B). These are accorded standard nomenclature for the fold, which comprises eight β -strands (β 1-8); three major helices (α A, α B and α C); a short helical turn overlaying the phosphate moiety (α P) and an N-terminal helical element (α N). Figure 3C delineates the residues within each structural element, with those from CBD2 referenced using a suffixing quotation mark (*e.g.* α A'). The asymmetric unit of the *Pf*PKA-R.141.441 crystals contained two protomers related by non-crystallographic symmetry whose structural differences are limited to different side chain conformations within surface residues. During the refinement of *Pf*PKA-R the unbiased omit maps showed cAMP molecules clearly occupying each domain's nucleotide-binding site (Fig. 4A,B). Thus our structure represents the dissociated nucleotide-bound state of the regulatory subunit.

In CBD1 (Fig. 4B) a conserved phosphate binding cassette (PBC) pincers the cyclophosphate moiety of cAMP between the N-terminus of the α P helix and a conserved arginine (Arg-268), a position that also facilitates the formation of a H-bond between the cAMP hydroxyl group and Glu-259. The residues making up these PBC-interactions are highly conserved across different CBD modules with equivalent residues present in CBD2 (α P', Arg-386' and Glu-377' respectively). The cyclic-nucleotides adenosine base projects outward where it is clamped on one side by hydrophobic residues originating from the β 4- β 5 loop (Ile-236 and Leu-248 in CBD1 and Ile-366' in CBD2). On the other side the base is clamped by a hydrophobic capping residue, the origin of which is an important point of distinction between the CBD1 and CBD2 binding sites: within CBD2 the cAMP' molecule is extensively buried by the subunit's C-terminal helix which overlays across it. This α C' helix is positioned such that Tyr-424' forms a critical base-stacking interaction (Fig. 4A), which along with Val-427' and Leu-428' creates an enclosed hydrophobic cAMP-binding site within this domain. C-terminal to α C' a kink in the backbone structure brings Cys-437' and Ile-438' back into proximity where they interact with cAMP near its N1-C2-N3 edge. The CBD2 binding site is thus hydrophobic, masks the nucleotide from solvent and is entirely self-contained (the structure of *Pf*PKA-R.297.441 is essentially CBD2 by itself in complex with cAMP, Fig. 4D). In contrast the CBD1 binding site is far more open and solvent exposed, Tyr-319' provides an analogous base-stacking hydrophobic cap (Fig. 4B) but importantly this residue actually originates from the N-terminus of the CBD2 domain's α A' helix. The α A' helix also contributes a second

charged H-bond interaction between Asp-317' and the N6 amide. Direct allosteric inter-domain interactions are thus required to form the nucleotide-binding site of CBD1.

Comparison with other known PKA regulatory subunits

We compared the malarial *Pf*PKA regulatory subunit structure with those of mammalian and yeast orthologues: that of *B. taurus* PKA type RI α (16) (25), *R. norvegicus* type RII β (26) and *S. cerevisiae* Bcy1 (27). Nucleotide-free holoenzyme structures of the mammalian orthologues are also known (17) (21) and were instrumental in elucidating the molecular basis of PKA signalling (Supp. Fig. 1). When RI α and RII β are in complex with their shared kinase domain their structures align with their tandem CBDs lying separated on either end of their respective straight conjoined α B/C helices. This rigid helix, along with their α A' and α B' helices, forms a binding site for the large lobe of the catalytic domain (21) (Supp. Fig 1A). cAMP-binding collapses this dumbbell shape, with the previously co-linear α B/C helix bending to reduce its length by up to 20% (Supp. Fig 1B). This moves the CBD modules into contact with each other masking their α A' and α B' KD-interacting surfaces, creating the active cAMP-bound form of their regulatory subunit, a form also reported for yeast Bcy1 (27). While the two mammalian orthologues adopt similar structures in their kinase-associated state (17) (21) the CBD modules collapse together utilising different orientations upon cAMP binding. In RI α cAMP induces a bend in the previously rigid helix between α B and α C (Supp. Fig. 1B), while in RII β the bend occurs midway along α C. This distinction is important as it influences how their respective CBD2 modules rotate in the

cAMP-collapsed state. In RI α the N-terminus of $\alpha A'$ moves to become proximal to the cAMP base of CBD1 (17) (Fig. 5A), providing a hydrophobic-capping tryptophan that plays a role similar to that of Tyr-319' in *PfPKA-R* (Fig. 5B). In contrast, the bending mechanism of RII β moves the N-terminus of its $\alpha B'$ helix next to the adenine ring, capping it with an underlying arginine (21) in an orientation perpendicular to that of RI α (Fig. 5C). Our cAMP-bound structure of *PfPKA-R* mimics RI α most closely (see Fig. 4C). *Plasmodium* and RI regulatory subunits both interact with the adenine ring of cAMP via aromatic N-terminal $\alpha A'$ residues, whereas the RII isoforms utilise an $\alpha B'$ arginine (Fig. 5C).

PfPKA-R also has RII β -like features as each have long $\alpha C'$ helix that extensively bury their respective CBD2 nucleotide. In *PfPKA-R* and RII β the $\alpha C'$ helix is twice the length of that of RI α . In *PfPKA-R* the first cAMP-binding site could thus be considered more similar to that of mammalian RI isoforms while the second site could be considered more reminiscent of RII (Fig. 5). Both nucleotide-binding sites are important for signalling within the vertebrate PKA regulatory subunits (22). In their holoenzyme state the CBD2 or "B" domain acts as a "gatekeeper", lying exposed and ready for binding due to residues within the nucleotide-clamping $\alpha C'$ helix being disordered (21,28). In *PfPKA-R* the $\alpha C'$ helix displays a degree of flexibility even in its cAMP-bound state, if we align the CBD2 domains from all protomers of our structures there are slight relative movements within $\alpha C'$ residues (Fig. 4D). This appears to arise from slight deviations in backbone hydrogen-bond distances from those of an ideal α -helix for the clamping residue Tyr-424'.

PfPKA-R shares ~39% sequence identity with mammalian type I and II isoforms but also displays a similar level of identity with the yeast regulatory subunit Bcy1 (27). Despite sharing similar levels of sequence identity with Bcy1 and both being unicellular, *PfPKA-R* demonstrates closer structural homology to the mammalian regulatory subunits than that of yeast.

The kinase domain interaction site

Overall, the *PfPKA-C* subunit shares ~50% sequence identity with the mammalian catalytic subunits. However, residues orthologous to those at the intersubunit docking interface of the mammalian holoenzymes are almost stringently conserved. The cAMP-bound structures of RI and RII subunits are distinct, yet their holoenzyme forms overlay. As the cAMP-bound forms of *PfPKA-R* and mammalian RI α also overlay (R.M.S.D. of 2.7Å over 227C α) it appears likely that the more stringently conserved holoenzyme docking interface will also closely resemble that of the mammalian isoforms.

In mammalian PKA's an inhibitory pseudosubstrate region extends away from the CBDs and docks into the kinase domain (17) (21). Upon cAMP-binding and dissociation these residues contract against CBD1 creating a "parked" conformation stabilised via an arginine within the preceding linker interacting with negatively charged surface presented by αB , an interaction that facilitates PKA activation (29). cAMP-bound *PfPKA-R* adopts an equivalent "parked" intermolecular linker but the interactions stabilising its association with CBD1 are distinct; αB being primarily contacted by hydrophobic linker residues (Pro-167 and Val-169).

The sequence of the *Pf*PKA-R pseudosubstrate residues (¹⁴⁵KKRLSVS¹⁵¹, see Fig. 3C) are most similar to the equivalent region of mammalian RI: they lack the flexible glycines of the RII sequence and Ser-149 corresponds to the γ -phosphate-interacting serine of RI. Consistent with this assumption phosphorylation of Ser-149 by *Pf*PKA-C and Ser-151 by *Pf*PKG is known to mitigate the inhibitory action of the *Pf*PKA-R pseudosubstrate region (15). Although present in our construct, we were not able to observe what form these residues take perhaps indicating that they may be only partially ordered in the dissociated cAMP-bound state.

Cyclic-AMP affinity measurements

We developed the purification protocol described for apo-*Pf*PKA-R.141.441 to eliminate scavenging of cyclic nucleotides from the bacterial lysate, representing a conformation of the subunit primed for binding to the catalytic subunit. We next ascertained the binding kinetics of cAMP to this form of the *Pf*PKA-R. Protein sample at $\sim 25\mu\text{M}$ within the cell of a Microcal isothermal titration calorimeter was titrated against sequential injections of cAMP (Fig. 6A).

Approximate equilibrium thermodynamics for cAMP binding to *Pf*PKA-R can be determined from the calorimetry data by fitting to the appropriate binding model. cAMP binding resulted in an isotherm that was clearly uniphasic and was able to be fit with a single-site interaction model having ligand stoichiometry of 2.1 ± 0.1 . If two binding-sites are known to be distinct a uniphasic isotherm typically results from positive cooperativity between the independent binding sites. This can cause a tendency for the sites within each

molecule to saturate together with a single enthalpic change of $\Delta H_1 + \Delta H_2$ (30). In such circumstances fitting to a single-site interaction model is more robust and provides the binding constant for only the lowest affinity site; in our case yielding a K_d of ~ 1 nM (see Table 2) for the tandem CBDs of *Pf*PKA-R. Repeating the experiment for the CBD2 domain in isolation (Fig. 6B, Table 2) indicated the presence of only a single cAMP binding site with a nearly equivalent K_d of ~ 6 nM and is consistent with it being the binding site first occupied by cAMP.

Inhibition of PfPKA-R blocks parasite proliferation.

Differences between the cAMP binding sites of *Pf*PKA-R and other eukaryotes raised the possibility that the subunit could be chemically exploited to dysregulate PKA signalling and arrest parasite proliferation. To evaluate this *P. falciparum* chloroquine sensitive and resistant strains 3D7 and W2mef respectively, were grown in the presence of four membrane permeable, cyclic nucleotide phosphodiesterase (PDE) resistant cAMP analogues for 72 h. As a marker for parasite proliferation, the levels of lactate dehydrogenase activity were measured at different drug concentrations to calculate an EC_{50} for growth. The most potent compound with an EC_{50} of $3.71\ \mu\text{M}$ was Sp-2-Cl-cAMPS followed by Sp-8-Br-cAMPS with an EC_{50} of $11.30\ \mu\text{M}$ for 3D7 parasites (Fig. 7A). The cAMP analog 6-Bnz-cAMP was only weakly inhibitory at highest concentrations (Fig. 7A). The generic PKA-C inhibitor H89 was included as a positive control as it had already been demonstrated to inhibit parasite growth (14) and with an EC_{50} $5.76\ \mu\text{M}$ was of similar potency as Sp-2-Cl-cAMPS (Fig 7A).

H89, Sp-2-Cl-cAMPS and Sp-8-Br-cAMPS blocked the proliferation of W2mef parasites nearly as well as 3D7 demonstrating the compounds are effective against multiple parasite strains (data not shown).

Sp-2-Cl-cAMPS relieves the allosteric inhibitory activity of Pf-PKA-R

To provide evidence that the mechanism of action of the cAMP analogs was through dysregulation of PfPKA-R function we sought to determine if the analogs could reverse the inhibitory effects of supplementary apo-PfPKA-R in *in vitro* PKA-dependent phosphorylation assays. The phosphorylation assays were performed as in Fig. 2 with parasite lysate providing the kinase source, the tail of AMA1 being the protein substrate and a phospho S610 antibody being the detector. The growth inhibitory Sp-2-Cl-cAMPS and Sp-8-Br-cAMPS compounds were tested alongside a cAMP control and PfPKA dependent phosphorylation of the AMA1 substrate was reconstituted in their presence (Fig. 7B-D). If the cAMP analogs act on PfPKA-R directly then they would be expected to alleviate the addition of supplementary apo-PfPKA-R.141.441. Following the addition of 0.5 or 1.5 μ M of PfPKA-R, high concentrations of Sp-2-Cl-cAMPS and cAMP were effective at alleviating the subunit's allosteric inhibitory action with the analog being as effective as cAMP (Fig. 7B and D). Interestingly, the second analog Sp-8-Br-cAMPS had difficulty overcoming apo-PfPKA-R supplementation (Fig. 7C). We repeated the isothermal titration calorimetry experiments with both analogs and found that Sp-2-Cl-cAMPS bound to the CBD2 domain of PfPKA-R with a K_d of \sim 9 nM (Fig. 6C, Table 2) equivalent to that of cAMP. Moreover it bound effectively to both sites within the

tandem CBD construct (Table 2). In contrast Sp-8-Br-cAMPS had no detectable affinity for the CBD2 site of PfPKA-R (Fig. 6D) and only bound the longer construct at a single site, presumably CBD1, with a K_d of 1.2 μ M.

Sp-2-Cl-cAMPS binding to CBD2

Finally we examined the mechanism of Sp-2-Cl-cAMPS binding to the CBD2 domain of PfPKA-R. Ligand-bound CBD2 crystals gave the best diffraction but still displayed significant anisotropy (2.4 Å on two axes and 3.8 Å resolution on the c axis). This was sufficient to allow a tentative model to be built and indicated Sp-2-Cl-cAMPS binding occurs in an almost identical manner as cAMP (Fig. 7E). The thiophosphate modification is accommodated without obvious changes (Fig. 7E). The additional chlorine on the adenosine's C2 carbon potentially requires a slight shift of the proteins extreme C-terminal residues (437'-441') to be accommodated (Fig. 7D,E); Our 1.1Å cAMP-bound structure would indicate a close contact if the C-terminus were to remain entirely stationary, but this movement is relatively minor. The remaining interactions of the binding site including the base-stacking interaction with Tyr-424' appear largely unchanged. Residues 437'-441' are not directly associated with any crystal packing interface.

If we overlay the structures of the other cAMP analogs tested onto our cAMP-bound structures it indicates that unlike Sp-2-Cl-cAMPS they could not be accommodated without more serious structural changes. The hydroxyl group of Tyr-369' makes a direct van der Waals contact with the C8 carbon and may be the cause for the reduced affinity for 8-

Bromoadenosine analogues within CBD2. In contrast there is no obvious hindrance to Sp-8-Br-cAMPS binding within the *Pf*PKA-R CBD1 site. During the more extended growth assays this may be sufficient to effect a reasonable growth arrest (Fig. 7A) yet is insufficient to strongly alleviate the addition of recombinant *Pf*PKA-R within the phosphorylation assay (Fig. 7C). Our structures suggest Sp-2-Cl-cAMPS could be accommodated in both CBD sites.

In vertebrate PKA's 6-Bnz-cAMP is selective for the CBD1 or "A" site, yet our assays suggest it is ineffective at inducing growth arrest via interaction with *Pf*PKA-R (Fig. 7A). It would clearly not be accommodated within CBD2 and a charged H-bond between Asp-317' and the N6-amide of cAMP may also limit its ability to interact within CBD1.

Discussion

The conserved cAMP-dependent protein kinases are a major regulator of signal transduction that arose prior to the origin of multi-cellularity in eukaryotes. Modern day unicellular eukaryotes often contain only a single catalytic/regulatory subunit pair but the increased requirement for signalling complexity in multicellular organisms such as vertebrates appears to have developed hand-in-hand with multi-component PKA signalling systems forged from gene duplications and subsequent isoform specialisation (32). The structures of PKA regulatory subunits from vertebrates and *S. cerevisiae* have previously been compared (27) with the latter seen to have a novel fungal-specific quaternary structure and allosteric activation mechanism. The structure of the *P.*

falciparum PKA regulatory subunit represents the first from a human pathogen as well as that of a species evolutionary distant from previously studied vertebrate and yeast orthologues (16,17,21,25,26,33).

In mammalian PKAs the two binding sites of the R subunits display positive cooperativity upon cAMP binding. The C-terminal CBD2, or "B" site, is always exposed and immediately available for nucleotide binding. When this site is occupied it stabilises structural changes within CBD1 that drastically increase its affinity for cAMP and promote subunit dissociation and hence activation (22). Our isothermal titration calorimetry data is consistent with *Pf*PKA-R utilising a similar two-state cooperative binding mechanism that provides an enthalpically driven interaction with nanomolar affinity for cAMP, as in vertebrates (34). Our structure of cAMP-bound *Pf*PKA-R.141.441 is consistent with this and details the interdomain interactions between the CBD modules.

The compact cAMP-bound conformation of *Pf*PKA-R has features reminiscent of both mammalian regulatory subtypes. The allosteric interface that creates the CBD1 nucleotide-binding site resembles that of RI (27). This may be indicative of it being the more ancestral allosteric regulatory architecture, with the orthogonal CBD interaction of RII isoforms and that of Bcy1 perhaps later evolutionary developments. Meanwhile the self-contained CBD2 binding site of *Pf*PKA-R extensively buries its adenosine base using a large hydrophobic C-terminal helix in a manner similar to that of the RII isoforms yielding a hybrid set of vertebrate features. The differences between the cAMP-binding

sites of RI and RII have led others to identify compounds that selectively activate the different mammalian isoforms; cAMP analogues containing N6-substitutions preferentially bind RII while C8-substitutions target type RI (35). The CBD1 domain of *PfPKA-R* is relatively open within the plane of the base and accordingly may accommodate a number of adenosine-modified cAMP analogs. In contrast the adenosine base within the CBD2 domain is extensively buried in our structures with C2 modified bases appearing to be most easily accommodated.

We then showed that some membrane-permeable cAMP analogues disrupt *P. falciparum* growth; thus while PKA activity is necessary for parasite growth the timing of that activity is also critical. It would be appealing to identify ligands that more selectively target *PfPKA-R* than those of their human host. Our Sp-2-Cl-cAMPS bound structure highlights one of the unique features of the CBD2 cAMP-binding site in *Plasmodium sp.*; the proximity of Cys-437' and its interactions near C2 of the adenosine base. Due to the conservation of Cys-437' amongst *Plasmodium* species it may stand as a useful point-of-difference that could be productively targeted when attempting to create *Plasmodium*-specific PKA activators. The action of Sp-2-Cl-cAMPS on PKA phosphorylation demonstrates that C2 modifications near Cys-437' are well tolerated and disrupt erythrocytic stage parasite growth at low micromolar concentrations.

Erythrocytic stage *P. falciparum* growth was effectively inhibited by Sp-2-Cl-cAMPS, however the therapeutic potential of this compound is reduced by its potential to influence human R

isoforms. Given the low similarity of *PfPKA-R* to orthologous human proteins more specific allosteric agonists could, in theory, be developed. Our current work focuses on direct interference of cAMP sensing, yet the phosphate binding cassettes are a highly conserved part of the fold. Greater specificity may be obtained by targeting compounds to other sites within *PfPKA-R* such as near the inter-CBD interface or the intermolecular linker N-terminal to CBD1. Moreover the function of the *PfPKA-R* N-terminus and its essentiality to the parasite remain to be ascertained.

Despite their divergent evolutionary history, the regulatory architecture of PKA signalling in *Plasmodium* parasites and their hosts bears recognisable similarities. We provide a first glimpse at the molecular details of cAMP signalling in a major human pathogen and detail the residues involved in providing allosteric cooperativity between its two CBD domains. Moreover while compounds blocking the kinase activity of *PfPKA-C* are known to limit parasite growth (14), we herein demonstrate that uncontrolled premature activation of *PfPKA-R* is equally disruptive to parasite survival.

MATERIALS AND METHODS

Protein cloning and expression - Synthetic cDNA encoding the *Plasmodium falciparum* 3D7 PKA regulator subunit (PF3D7_1436600) was cloned into pET-28b based expression vector. Five different constructs were made consisting of PKAR residues 1-441, 69-441, 141-441, 297-441 and 141-297. Recombinant protein was expressed in *E. coli*

BL21(DE3) cells grown for 4 hours at 37°C in Luria Broth containing 34 µM kanamycin before being induced for 4 hours with 0.1 mM Isopropyl thiogalactopyranoside. Cells were harvested and resuspended in buffer A (20 mM HEPES pH 7.5, 250 mM NaCl, 1 mM TCEP) with 20 mM imidazole prior to lysis with 1 mg/mL lysozyme and DNAase along with 5 min sonication on ice; cell lysate was clarified by centrifugation and loaded onto immobilised metal affinity column with the bound material then washed extensively with Buffer A before being eluted in Buffer supplemented with 400 mM Imidazole. After elution from the IMAC column the hexahistidine tag was removed by incubating at 4°C overnight with 0.5 mg human rhinovirus-3c protease. After exchanging into 20 mM HEPES pH 7.5, 50 mM NaCl, 1 mM TCEP *Pf*PKA-R was loaded onto a 1 mL HiTrap-SP cation exchange column and eluted under a 25 mL gradient to buffer A with 1M NaCl. Protein eluted as a single peak and was subsequently loaded onto size exclusion chromatography column equilibrated with Buffer A.

When *apo Pf*PKA-R was required the protein was purified as per normal but after loading onto the IMAC column bound material was washed extensively with 20 mM HEPES pH 7.5, 8M urea, 250mM NaCl, 1mM TCEP before slowly exchanging back into buffer A.

Culture of *Plasmodium falciparum* - *P. falciparum* asexual stage parasites were cultured in human erythrocytes (blood group O+) supplied by the Australian Red Cross Blood Bank at 4% haematocrit in RPMI-HEPES medium supplemented with 0.43% AlbumaxII Lipid Rich Bovine Serum (GIBCO) and 0.18% NaHCO₃ as previously described (36). Lysates for

phosphorylation were made from late stage schizonts 42-46 hours post invasion at 2% parasitemia. The schizonts were treated with 0.09% saponin in PBS and Roche Complete protease inhibitors to lyse the membranes of their erythrocytes. The erythrocyte contents including hemoglobin and human PKA were removed by washing the parasite cells multiple times in PBS and frozen at -80°C. Immediately prior to performing phosphorylation reactions the parasite pellets were thawed in 20mM Tris pH 7.4, 1% Triton, 150mM NaCl, 20mM MgCl₂, 1mM ATP, 1mM DTT with Roche PhosSTOP phosphatase inhibitors and Roche Complete protease inhibitors. Before use the lysates were cleared by centrifugation and a volume equivalent to 0.2 µL of pelleted saponin lysed schizonts was used per reaction (see below).

Functional validation of recombinant *Pf*PKA-R - Nunc MaxiSorp 96 well ELISA plates were coated with 1µg/ml of GST-*Pf*AMA1 (8) substrate overnight at 4°C. Coated plates were subsequently blocked in 1% bovine serum albumin (BSA) in tris-buffered saline (TBS) for 1 h prior to initiation of phosphorylation reactions in kinase activity buffer (20 mM Tris, 20 mM MgCl₂, 2 mM MnCl₂, 1 mM DTT, Roche PhosSTOP) supplemented with lysates made from *P. falciparum* late stage schizonts and 100µM ATP and 0-8µM cAMP. Recombinant *Pf*PKA-R (5, 1.5, 0.5 or 0 µM) was titrated in to the phosphorylation reactions in either an active or heat-inactivated state (70°C/15 mins prior to placement on ice/10 mins) at 37°C/30 mins. Following the reaction the wells were washed three times with TBS and probed with rabbit anti-phospho-*Pf*AMA1_{S610} antibodies raised to the synthetic peptide SFWGEEKRASpHTTPV phosphorylated on the S610 residue

(Genscript). The resulting antisera had been depleted of non-phospho-specific antibodies by depletion against a non-phosphorylated version of the peptide (Genscript). The ELISA plates were washed as before and subsequently probed with goat anti-rabbit-HRP (Abcam) at room temperature/shaking. Following washing, 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) was added (30 min/shaking) to develop the assay and the reaction was stopped by addition of 1% SDS before reading at 405nm on a spectrophotometer. Absorbance values were plotted in Prism 6 (GraphPad).

Parasite proliferation assays - Asexual blood stage *P. falciparum* parasites were cultured for 72 h in a dilution series of cAMP analogs Sp-8-Br-cAMPS (8-bromoadenosine- 3', 5'- cyclic monophosphorothioate, Sp-isomer [CalBiochem]), 6-Bnz-cAMP (N6-benzoyladenine- 3', 5'- cyclic monophosphate [BioLog]) and Sp-2-Cl-cAMPS (2- chloroadenosine- 3', 5'- cyclic monophosphorothioate, Sp-isomer [BioLog]). H-89 dihydrochloride hydrate was from Sigma. After culturing lactate dehydrogenase activity was measured using a modified form of the Malstat assay (23,37).

Protein crystallisation - PfPKA-R.141.441 at 12 mg/mL with 2mM cAMP was crystallised at 4°C within a hanging drop vapour diffusion experiment. Protein drops were set in a 1:1 ratio against a reservoir consisting of 20% w/v Polyethylene glycol 3350, 0.1M NaF and 0.1M 1,3-bispropane pH 7.5, with crystals appearing after 7-10 days. Crystals were transferred into a cryoprotectant consisting of reservoir and 250 mg/mL

sucrose before being plunged into liquid nitrogen.

PfPKA-R.297.441 at 4 mg/mL with 2mM cAMP also crystallised at 4°C in a similar experiment using a reservoir consisting of 22% w/v polyethylene glycol 6000, 0.1M LiCl and 0.1M CH₃COONa pH 4. Apo-PfPKA-R.297.441 without removal of the his-tag at 6 mg/mL with 2mM Sp-2-Cl-cAMPS was crystallised at 22°C over a reservoir consisting of 20% w/v polyethylene glycol 3350, 0.2M NH₄I. Prior to being plunged into liquid nitrogen crystals were transferred into a solution containing 250 mg/mL sucrose as cryoprotectant.

Data collection and structure solution - X-ray diffraction data was collected at the Australian synchrotron MX1 and MX2 beamlines. Data was integrated and scaled with the programs imosflm and Scala. A trimmed version of the bovine PKA-R subunit (16) was used as a molecular replacement probe in the program Phaser (38). The resulting model was then improved by simulated annealing and rounds of manual building and refinement using the programs COOT (39) and PHENIX (40). The final PfPKA-R.297.441 model has two protomers in the ASU, with all residues observed along with two molecules of cAMP. The final PfPKA-R.141.441 model consists of two molecules within the asymmetric unit with clear electron density for residues 167-441, 4 molecules of cAMP and 4 tentatively identified N-terminal residues.

Isothermal titration calorimetry - Apo PfPKA-R.141.441 or PfPKA-R.297.441 were purified, concentrated and finally dialyzed overnight against buffer containing 20 mM HEPES, pH 7.0, 150 mM NaCl, 0.5mM TCEP. After dialysis the

protein concentration was adjusted to ~0.026 mM. Cyclic nucleotides used for titration were prepared using the dialysis buffer to a final concentration of 0.5 mM. ITC measurements were performed with a MicroCal VP-ITC calorimeter (GE Healthcare) at 25°C. Nucleotides were injected 50-70 times (1 µL for the first two injections and 2 µL for subsequent injections), with 240 s intervals between

injections. Background data obtained from the buffer sample were subtracted before data analysis. All data were fitted using the Origin 7.0 software package (MicroCal, Northampton, MA). Two independent measurements were performed with errors representing the standard deviation of fitted constants.

Acknowledgements

This work was performed with the help of the staff of the Australian synchrotron MX1 and MX2 beamlines. We appreciate support from the National Health and Medical Research Council of Australia (NHMRC) Project grant (APP1068287) and funding from the Victorian Operational Infrastructure Support Program received by the Burnet Institute. We thank the Australian Red Cross Blood Bank for the provision of human blood.

Author Contributions

D.R.L. performed recombinant protein expression, calorimetry, crystallization, data collection and model refinement. H.B., P.G. and K. H. performed *Plasmodium* growth and kinase assays. J.R., T.B., B.C., D.R.L, and P.G. analyzed data and wrote the manuscript.

Declaration of interest

The Authors declare that they have no conflicts of interest with the contents of this article.

Accession Numbers

Structural coordinates have been deposited in the PDB under the ID codes 5KBF and 5K8S.

References

1. WHO. (2014) *World Malaria report* World Health Organization, Geneva, Switzerland
2. Committee, W. H. O. M. P. A., and Secretariat. (2016) Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of eighth biannual meeting (September 2015). *Malaria journal* **15**, 117
3. Solyakov, L., Halbert, J., Alam, M. M., Semblat, J. P., Dorin-Semblat, D., Reininger, L., Bottrill, A. R., Mistry, S., Abdi, A., Fennell, C., Holland, Z., Demarta, C., Bouza, Y., Sicard, A., Nivez, M. P., Eschenlauer, S., Lama, T., Thomas, D. C., Sharma, P., Agarwal, S., Kern, S., Pradel, G., Graciotti, M., Tobin, A. B., and Doerig, C. (2011) Global kinomic and phospho-proteomic analyses of the human malaria parasite *Plasmodium falciparum*. *Nature communications* **2**, 565
4. van Dooren, G. G., and Striepen, B. (2013) The algal past and parasite present of the apicoplast. *Annual review of microbiology* **67**, 271-289
5. Lucet, I. S., Tobin, A., Drewry, D., Wilks, A. F., and Doerig, C. (2012) *Plasmodium* kinases as targets for new-generation antimalarials. *Future medicinal chemistry* **4**, 2295-2310

6. Hopp, C. S., Bowyer, P. W., and Baker, D. A. (2012) The role of cGMP signalling in regulating life cycle progression of Plasmodium. *Microbes and infection / Institut Pasteur* **14**, 831-837
7. Lasonder, E., Green, J. L., Camarda, G., Talabani, H., Holder, A. A., Langsley, G., and Alano, P. (2012) The Plasmodium falciparum schizont phosphoproteome reveals extensive phosphatidylinositol and cAMP-protein kinase A signaling. *Journal of proteome research* **11**, 5323-5337
8. Leykauf, K., Treeck, M., Gilson, P. R., Nebl, T., Braulke, T., Cowman, A. F., Gilberger, T. W., and Crabb, B. S. (2010) Protein kinase a dependent phosphorylation of apical membrane antigen 1 plays an important role in erythrocyte invasion by the malaria parasite. *PLoS pathogens* **6**, e1000941
9. Lasonder, E., Green, J. L., Grainger, M., Langsley, G., and Holder, A. A. (2015) Extensive differential protein phosphorylation as intraerythrocytic Plasmodium falciparum schizonts develop into extracellular invasive merozoites. *Proteomics* **15**, 2716-2729
10. Dawn, A., Singh, S., More, K. R., Siddiqui, F. A., Pachikara, N., Ramdani, G., Langsley, G., and Chitnis, C. E. (2014) The central role of cAMP in regulating Plasmodium falciparum merozoite invasion of human erythrocytes. *PLoS pathogens* **10**, e1004520
11. Beraldo, F. H., Almeida, F. M., da Silva, A. M., and Garcia, C. R. (2005) Cyclic AMP and calcium interplay as second messengers in melatonin-dependent regulation of Plasmodium falciparum cell cycle. *The Journal of cell biology* **170**, 551-557
12. Merckx, A., Nivez, M. P., Bouyer, G., Alano, P., Langsley, G., Deitsch, K., Thomas, S., Doerig, C., and Egee, S. (2008) Plasmodium falciparum regulatory subunit of cAMP-dependent PKA and anion channel conductance. *PLoS pathogens* **4**, e19
13. Ramdani, G., Naissant, B., Thompson, E., Breil, F., Lorthiois, A., Dupuy, F., Cummings, R., Duffier, Y., Corbett, Y., Mercereau-Puijalon, O., Vernick, K., Taramelli, D., Baker, D. A., Langsley, G., and Lavazec, C. (2015) cAMP-Signalling Regulates Gametocyte-Infected Erythrocyte Deformability Required for Malaria Parasite Transmission. *PLoS pathogens* **11**, e1004815
14. Syin, C., Parzy, D., Traincard, F., Boccaccio, I., Joshi, M. B., Lin, D. T., Yang, X. M., Assemat, K., Doerig, C., and Langsley, G. (2001) The H89 cAMP-dependent protein kinase inhibitor blocks Plasmodium falciparum development in infected erythrocytes. *European journal of biochemistry / FEBS* **268**, 4842-4849
15. Haste, N. M., Talabani, H., Doo, A., Merckx, A., Langsley, G., and Taylor, S. S. (2012) Exploring the Plasmodium falciparum cyclic-adenosine monophosphate (cAMP)-dependent protein kinase (PfPKA) as a therapeutic target. *Microbes and infection / Institut Pasteur* **14**, 838-850
16. Su, Y., Dostmann, W. R., Herberg, F. W., Durick, K., Xuong, N. H., Ten Eyck, L., Taylor, S. S., and Varughese, K. I. (1995) Regulatory subunit of protein kinase A: structure of deletion mutant with cAMP binding domains. *Science* **269**, 807-813
17. Kim, C., Cheng, C. Y., Saldanha, S. A., and Taylor, S. S. (2007) PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. *Cell* **130**, 1032-1043
18. Reimann, E. M., Walsh, D. A., and Krebs, E. G. (1971) Purification and properties of rabbit skeletal muscle adenosine 3',5'-monophosphate-dependent protein kinases. *The Journal of biological chemistry* **246**, 1986-1995

19. Amieux, P. S., and McKnight, G. S. (2002) The essential role of RI alpha in the maintenance of regulated PKA activity. *Annals of the New York Academy of Sciences* **968**, 75-95
20. Berman, H. M., Ten Eyck, L. F., Goodsell, D. S., Haste, N. M., Kornev, A., and Taylor, S. S. (2005) The cAMP binding domain: an ancient signaling module. *Proceedings of the National Academy of Sciences of the United States of America* **102**, 45-50
21. Zhang, P., Smith-Nguyen, E. V., Keshwani, M. M., Deal, M. S., Kornev, A. P., and Taylor, S. S. (2012) Structure and allostery of the PKA RIbeta tetrameric holoenzyme. *Science* **335**, 712-716
22. Akimoto, M., McNicholl, E. T., Ramkissoon, A., Moleschi, K., Taylor, S. S., and Melacini, G. (2015) Mapping the Free Energy Landscape of PKA Inhibition and Activation: A Double-Conformational Selection Model for the Tandem cAMP-Binding Domains of PKA RIalpha. *PLoS biology* **13**, e1002305
23. Buskes, M. J., Harvey, K. L., Richards, B. J., Kalhor, R., Christoff, R. M., Gardhi, C. K., Littler, D. R., Cope, E. D., Prinz, B., Weiss, G. E., O'Brien, N. J., Crabb, B. S., Deady, L. W., Gilson, P. R., and Abbott, B. M. (2016) Antimalarial activity of novel 4-cyano-3-methylisoquinoline inhibitors against *Plasmodium falciparum*: design, synthesis and biological evaluation. *Organic & biomolecular chemistry*
24. Howard, B. L., Harvey, K. L., Stewart, R. J., Azevedo, M. F., Crabb, B. S., Jennings, I. G., Sanders, P. R., Manallack, D. T., Thompson, P. E., Tonkin, C. J., and Gilson, P. R. (2015) Identification of potent phosphodiesterase inhibitors that demonstrate cyclic nucleotide-dependent functions in apicomplexan parasites. *ACS chemical biology* **10**, 1145-1154
25. Bruystens, J. G., Wu, J., Fortezzo, A., Kornev, A. P., Blumenthal, D. K., and Taylor, S. S. (2014) PKA RIalpha homodimer structure reveals an intermolecular interface with implications for cooperative cAMP binding and Carney complex disease. *Structure* **22**, 59-69
26. Diller, T. C., Madhusudan, Xuong, N. H., and Taylor, S. S. (2001) Molecular basis for regulatory subunit diversity in cAMP-dependent protein kinase: crystal structure of the type II beta regulatory subunit. *Structure* **9**, 73-82
27. Rinaldi, J., Wu, J., Yang, J., Ralston, C. Y., Sankaran, B., Moreno, S., and Taylor, S. S. (2010) Structure of yeast regulatory subunit: a glimpse into the evolution of PKA signaling. *Structure* **18**, 1471-1482
28. Ilouz, R., Bubis, J., Wu, J., Yim, Y. Y., Deal, M. S., Kornev, A. P., Ma, Y., Blumenthal, D. K., and Taylor, S. S. (2012) Localization and quaternary structure of the PKA RIbeta holoenzyme. *Proceedings of the National Academy of Sciences of the United States of America* **109**, 12443-12448
29. Akimoto, M., Selvaratnam, R., McNicholl, E. T., Verma, G., Taylor, S. S., and Melacini, G. (2013) Signaling through dynamic linkers as revealed by PKA. *Proceedings of the National Academy of Sciences of the United States of America* **110**, 14231-14236
30. Brautigam, C. A. (2015) Fitting two- and three-site binding models to isothermal titration calorimetric data. *Methods* **76**, 124-136
31. Badireddy, S., Yunfeng, G., Ritchie, M., Akamine, P., Wu, J., Kim, C. W., Taylor, S. S., Qingsong, L., Swaminathan, K., and Anand, G. S. (2011) Cyclic AMP analog blocks kinase activation by stabilizing inactive conformation: conformational selection

- highlights a new concept in allosteric inhibitor design. *Molecular & cellular proteomics : MCP* **10**, M110 004390
32. Soberg, K., Jahnsen, T., Rognes, T., Skalhegg, B. S., and Laerdahl, J. K. (2013) Evolutionary paths of the cAMP-dependent protein kinase (PKA) catalytic subunits. *PLoS one* **8**, e60935
 33. Wu, J., Jones, J. M., Nguyen-Huu, X., Ten Eyck, L. F., and Taylor, S. S. (2004) Crystal structures of R1alpha subunit of cyclic adenosine 5'-monophosphate (cAMP)-dependent protein kinase complexed with (Rp)-adenosine 3',5'-cyclic monophosphothioate and (Sp)-adenosine 3',5'-cyclic monophosphothioate, the phosphothioate analogues of cAMP. *Biochemistry* **43**, 6620-6629
 34. Moll, D., Schweinsberg, S., Hammann, C., and Herberg, F. W. (2007) Comparative thermodynamic analysis of cyclic nucleotide binding to protein kinase A. *Biological chemistry* **388**, 163-172
 35. Brown, S. H., Cheng, C. Y., Saldanha, S. A., Wu, J., Cottam, H. B., Sankaran, B., and Taylor, S. S. (2013) Implementing fluorescence anisotropy screening and crystallographic analysis to define PKA isoform-selective activation by cAMP analogs. *ACS chemical biology* **8**, 2164-2172
 36. Trager, W., and Jensen, J. B. (1976) Human malaria parasites in continuous culture. *Science* **193**, 673-675
 37. Makler, M. T., and Hinrichs, D. J. (1993) Measurement of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia. *The American journal of tropical medicine and hygiene* **48**, 205-210
 38. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. *Journal of applied crystallography* **40**, 658-674
 39. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. *Acta crystallographica. Section D, Biological crystallography* **66**, 486-501
 40. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta crystallographica. Section D, Biological crystallography* **66**, 213-221

Table 1 - Data collection and refinement statistics

	PKAR.141.441	PKAR.297.441	PKAR.297.441
Data collection	cAMP bound	cAMP bound	Sp-2Cl-cAMPS bound
Space group	<i>P2₁2₁2</i>	<i>P2₁2₁2₁</i>	<i>P4₃2₁2</i>
Wavelength	0.9537	0.9537	0.9537
Cell dimensions ^{□□}			
<i>a</i> , <i>b</i> , <i>c</i> (Å)	78.7, 103.8, 104.2	39.3, 71.8, 106.5	64.2, 64.2, 195.7
Resolution (Å)	46.6-2.00 (2.11-2.00)	42.8-1.15 (1.21-1.15)	37.3-2.40 (2.53-2.40)
<i>R</i> _{pim} ¹	3.1 (55.5)	4.1 (44.0)	3.8 (31.6)
<i>I</i> / σ ₁	12.4 (1.6)	9.7 (1.8)	11.2 (2.2)
Completeness (%)	100.0 (100.0)	97.2 (89.5)	99.9 (100.0)
N ^o . unique observations	58452 (8419)	104403 (13799)	16863 (2389)
Multiplicity	9.0 (9.1)	7.9 (5.9)	11.2 (11.6)
Refinement statistics			
<i>R</i> _{factor} ² (%)	24.5 (36.0)	19.8 (29.0)	25.1 (32.3)
<i>R</i> _{free} ³ (%)	28.5 (37.8)	21.8 (33.2)	30.7 (38.1)
No. atoms			
Protein	4534	2469	2392
Water (cAMP)	36 (4)	356 (2)	10 (2 cAMPS; 5I)
Ramachandran plot (%)			
• Most favoured	97.1	98.7	96.1
• Allowed region	2.9	1.2	3.9
Outlier	0.0	0.0	0.0
B-factors (Å ²)			
• Protein	66.1	22.0	93.3
rmsd bonds (Å)	0.009	0.012	0.014
rmsd angles (°)	1.26	1.31	2.2
PDB	5KBF	5K8S	5T3N

$$^1 R_{p.i.m} = \sum_{hkl} [1/(N-1)]^{1/2} \sum_i |I_{hkl,i} - \langle I_{hkl} \rangle| / \sum_{hkl} \langle I_{hkl} \rangle$$

$$^2 R_{factor} = (\sum ||F_o| - |F_c||) / (\sum |F_o|) \text{ - for all data except as indicated in footnote 3.}$$

$$^3 5\% \text{ of data was used for the } R_{free} \text{ calculation}$$

Values in parentheses refer to the highest resolution bin

Table 2 - Isothermal calorimetry binding constants

Construct	Ligand	N	K_d (nM)¹	ΔH (kcal mol⁻¹)	ΔS (cal mol⁻¹ K⁻¹)
<i>Pf</i> PKAR.141.441	cAMP	2.1±0.1	1.2 ± 0.2	-18.9 ± 0.6	-22 ± 2
<i>Pf</i> PKAR.141.441	Sp-8-Br-cAMPS	1.2 ± 0.1	1300 ± 850	-10.5 ± 2	-8.1 ± 1.1
<i>Pf</i> PKAR.141.441	Sp-2-Cl-cAMPS	2.1 ± 0.1	8.9 ± 4	-11.9 ± 0.4	-3 ± 2
<i>Pf</i> PKAR.297.441	cAMP	0.9 ± 0.1	6.0 ± 0.6	-11.1 ± 0.1	-0.2 ± 0.3
<i>Pf</i> PKAR.297.441	Sp-8-Br-cAMPS	-	N.D.	N.D.	N.D.
<i>Pf</i> PKAR.297.441	Sp-2-Cl-cAMPS	0.9 ± 0.1	9.1 ± 11	-7.1 ± 0.1	11.7 ± 0.9

¹ Determined at 295K




Figure 1. Domain structure of Plasmodium PKA regulatory subunit.

Diagram of *Plasmodium falciparum* PKA regulatory (*PfPKA-R*) gene showing regions expressed for functional and structural analysis. (Left) *PfPKA-R* has two cAMP binding regions CBD1 and CBD2, inhibitory sequence (IS) and predicted N-myristoylation (Gly-2) and palmitoylation (Cys-5) sites for membrane anchorage. Four regions of *PfPKA-R* were expressed of which two generated high yield (right, 141-441/297-441).




Figure 2. Recombinant apo-*Pf*PKA-R inhibits PKA-mediated phosphorylation

(A) Illustration of the ELISA based phosphorylation assay using the recombinant tail of AMA1, a validated *Pf*PKA target. (B) Native phosphorylation activity of *Pf*PKA-C (indicated by OD 405 nm), can be efficiently inhibited by addition of recombinant apo-*Pf*PKA-R in a concentration-dependent manner. This effect can be efficiently reversed by addition of supplementary cAMP and is due specifically to the apo-*Pf*PKA-R as the inhibitory effect of the fragment is lost upon heat denaturation (heat inactivated). Each data point and whiskers are the mean/standard deviation of two technical replicates. Graph shown is representative of three independent biological replicates.




Figure 3 Structure of *Pf*PKA-R

A) Schematic representation of the mammalian PKA holoenzyme and its activation mechanism. Catalytic domain depicted in gray, CBD1 and CBD2 domains in blue and purple. **B)** Cartoon representation of the nucleotide bound *Pf*PKA-R structure. β -strands are coloured tan, CBD1 α -helices blue and CBD2 α -helices purple. All secondary structure elements are labelled within each CBD. The two bound cAMP molecules are shown in red. **C)** Sequence alignment of the residues within the respective CBD domains for the PKA-R subunits from *P. falciparum*, *P. vinckei vinckei*, *T. gondii*, and *H. sapiens* RI α and RIIB β . The conserved PBC arginines are highlighted in black, the α P glutamates and the tyrosine with which they interact in red, and the inhibitory sequence in pink.




Figure 4 Structure of the cAMP binding sites within *PpPKA-R*.

A) Residues within the cyclic-AMP binding site of CBD2 as observed within the 1.1Å *PpPKAR.297.441* structure. The nucleotide is clearly bound as seen in the $F_o - F_c$ omit map contoured at 3.4σ . The main residues contributing to the binding site are displayed in stick representation. **B)** The CBD1 cAMP-binding site as observed within the 2.0Å *PpPKAR.141.441* structure. Tyr-319 is highlighted. **C)** Backbone alignment of *PpPKA-R* with the orthologous cAMP-bound structure of *B. tarus* PKA-R (in green). The bound nucleotides of *BtPKA-R* are coloured light brown while *PpPKA-R* is depicted using the colour scheme of Fig. 2B. **D)** Potential mobility of the helical elements of the CBD2 domain can be seen when comparing an alignment of its structure ascertained from the different crystals.




Figure 5 - Comparison of the cAMP-binding domains in the known structures of PKA orthologues.

A) Cartoon representation of the A- or CBD1 cAMP-binding site from *Bos taurus* type RI α (25). Helices within CBD1 are coloured *aquamarine* and those within CBD2 *teal*, the bound cAMP is shown in *red*. The interdomain interfacial hydrophobic capping tryptophan contributed by $\alpha A'$ is shown in stick representation. Similar representations are presented for the CBD1 domains of **B)** *PfPKA*-R and **C)** *RnPKA*-R IIB (26). Similar representations of the CBD2 domains are presented for **D)** *BtPKA*-RI α . **E)** *PfPKA*-R and **F)** *RnPKA*-RIIB. *Yellow arrows* indicate the orthologue structures each malarial *PfPKA*-R binding domain is most similar to.




Figure 6 – Isothermal titration calorimetry affinity measurements

A) Binding isotherm measured at 295K for the interaction between cAMP and apo-*Pf*PKA-R.141.441, *below* is the resulting thermogram obtained from the integrated heats using a one-site binding model. Equivalent experiments for binding to the CBD2 site of apo-*Pf*PKA-R.297.441 are shown for **B)** cAMP, **C)** Sp-2-Cl-cAMPS and **D)** Sp-8-Br-cAMPS.




Figure 7. Compounds binding *Pf*PKA-R block parasite proliferation and causes PKA dysregulation. (A) Four cAMP analogs and the PKA-C inhibitor H89 were assessed for their capacity to block proliferation of the asexual blood stage of *P. falciparum* 3D7 parasite strain. After 72 h of growth in serial dilutions of the compounds the levels of the parasite enzyme lactate dehydrogenase were measured at OD650 nm and growth curves are presented. Mean EC₅₀s and SEMs for three replicates are shown on the right. (B-D) Cyclic AMP and its analogs can stimulate PKA phosphorylation. The level of phosphorylation of an immobilised AMA1 substrate was detected using an anti-phospho-AMA1 S610 protein and measured using an anti-rabbit HRP conjugate producing a colorimetric change quantified at 405 nm. Parasite lysate provided the source of PKA-C whose activity was stimulated with the compounds indicated. Supplementary recombinant apo-*Pf*PKA-R was added to verify if this protein was the target of the cAMP analogs whose structures are shown. Each data point and whiskers are the mean and standard deviations of duplicate measurements. Representative graphs of three independent experiments are shown. (E) The structure of Sp-2-Cl-cAMPS bound *Pf*PKA-R.297.441 is shown, residues capable of forming van der Waals interactions with the 2'-Cl are highlighted with black lines. Colouring and labelling are as used in Fig. 4A, the F_o-F_c omit map generated during refinement contoured at 3σ is displayed with a green surface representation. For clarity the 1st half of αC' is not displayed.